Tolvaptan, hyponatremia, and heart failure

@inproceedings{Zmily2011TolvaptanHA,
  title={Tolvaptan, hyponatremia, and heart failure},
  author={Hammam D Zmily and Suleiman Daifallah and Jalal K. Ghali},
  booktitle={International journal of nephrology and renovascular disease},
  year={2011}
}
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan inhibits the binding of arginine vasopressin to the V(2) receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. This article reviews the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Similar Papers

Loading similar papers…